DelveInsight’s, “Obstructive Sleep Apnea - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Obstructive Sleep Apnea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

    Geography Covered
    • Global coverage

    Obstructive Sleep Apnea Understanding
    Obstructive Sleep Apnea: Overview
    Obstructive sleep apnea (OSA) consists of episodes of partial or complete closure of the upper airway that occur during sleep and lead to breathing cessation (defined as a period of apnea or hypopnea > 10 seconds). Symptoms include excessive daytime sleepiness, restlessness, snoring, recurrent awakening, and morning headache. Diagnosis is based on sleep history and polysomnography. Treatment is with nasal continuous positive airway pressure, oral appliances, and, in refractory cases, surgery. Prognosis is good with treatment. Most cases remain undiagnosed and untreated and are often associated with hypertension, atrial fibrillation and other arrhythmias, heart failure, and injury or death due to motor vehicle crashes and other accidents resulting from hypersomnolence.

    "Obstructive Sleep Apnea - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obstructive Sleep Apnea pipeline landscape is provided which includes the disease overview and Obstructive Sleep Apnea treatment guidelines. The assessment part of the report embraces, in depth Obstructive Sleep Apnea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obstructive Sleep Apnea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


    Report Highlights
    • The companies and academics are working to assess challenges and seek opportunities that could influence Obstructive Sleep Apnea R&D. The therapies under development are focused on novel approaches to treat/improve Obstructive Sleep Apnea.

    Obstructive Sleep Apnea Emerging Drugs Chapters
    This segment of the Obstructive Sleep Apnea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

    Obstructive Sleep Apnea Emerging Drugs
    • AD036: Apnimed
    AD036, consisting of the norepinephrine reuptake inhibitor, atomoxetine, combined with the anti-muscarinic oxybutynin, was studied in a large Phase II clinical trial that included 140 patients with a broad range of OSA severity from moderate to very severe. AD036 improved multiple objective measures of OSA as well as OSA symptoms, providing proof-of-concept that an oral pharmacologic approach may have clinical benefit in patients with OSA.
    • THX-110: Therapix Biosciences
    THX-110 is a drug candidate platform for the treatment of symptoms related to Tourette syndrome (TS), as well as Obstructive Sleep Apnea (OSA) and chronic pain. The THX-110 program takes a unique approach to cannabinoid formulation using the “Entourage Effect” hypothesis (i.e. in which Endocannabinoid system constituents work synergistically together). THX-110 is a proprietary combination drug based on dronabinol and PEA. PEA is a cannabinoid mimetic lipid molecule, which naturally occurs in various plant and animal sources.
    Further product details are provided in the report??..

    Obstructive Sleep Apnea: Therapeutic Assessment
    This segment of the report provides insights about the different Obstructive Sleep Apnea drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players in Obstructive Sleep Apnea
    There are approx. 20+ key companies which are developing the therapies for Obstructive Sleep Apnea. The companies which have their Obstructive Sleep Apnea drug candidates in the most advanced stage, i.e. phase II include, Apnimed.
    • Phases
    DelveInsight’s report covers around 20+ products under different phases of clinical development like
    • Late stage products (Phase III)
    • Mid-stage products (Phase II)
    • Early-stage product (Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates
    • Route of Administration
    Obstructive Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Oral
    • Parenteral
    • intravenous
    • Subcutaneous
    • Topical.
    • Molecule Type

    Products have been categorized under various Molecule types such as
    • Monoclonal Antibody
    • Peptides
    • Polymer
    • Small molecule
    • Gene therapy
    • Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Obstructive Sleep Apnea: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obstructive Sleep Apnea therapeutic drugs key players involved in developing key drugs.
    Pipeline Development Activities
    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obstructive Sleep Apnea drugs.

    Obstructive Sleep Apnea Report Insights
    • Obstructive Sleep Apnea Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs

    Obstructive Sleep Apnea Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Obstructive Sleep Apnea drugs?
    • How many Obstructive Sleep Apnea drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obstructive Sleep Apnea?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Obstructive Sleep Apnea therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Obstructive Sleep Apnea and their status?
    • What are the key designations that have been granted to the emerging drugs?

    Key Players
    • Apnimed
    • Therapix Biosciences
    • Eisai
    • Idorsia Pharmaceuticals
    • Takeda
    • Merck & Co
    • Taisho Pharmaceutical Co., Ltd.
    • Bayer
    • Janssen Pharmaceuticals
    • RespireRx Pharmaceuticals
    • Cortex Pharmaceuticals
    • Michael James Enterprises

    Key Products
    • AD036
    • THX-110
    • Lemborexant
    • AD182
    • AD504
    • AD109
    • ACT-541468
    • TAK-925
    • Gefapixant
    • TS-142
    • BAY2586116
    • Seltorexant
    • Dronabinol low-dose
    • CX 1739
    • Dronabinol